


Heart failure can be hard to manage — **REMOTE MONITORING WITH THE CARDIOMEMS™ HF SYSTEM CAN HELP**

Do you have patients who identify with one or more of the statements below?

H	HEART FAILURE MEDICAL MANAGEMENT INEFFECTIVE	Real-time access to PA pressures empowers medical management for each patient
E	EXERTION LIMITED	Proven to improve exercise capacity and quality of life scores ^{1,2}
L	LIVE FAR FROM A CLINIC	Remote access to data informs clinical interventions — all while patients remain at home
P	PRESERVED OR REDUCED EJECTION FRACTION (EF)	Optimizes management of heart failure, even in patients with preserved EF ¹




“To know that someone is watching and helping me by looking at my numbers every day has made the biggest difference in my life.”


IRIS W. — implanted with the CardioMEMS HF System in 2015

Consider evaluation for the CardioMEMS™ HF System.



THE CARDIOMEMS™ HF SYSTEM IS THE ONLY REMOTE MONITORING PLATFORM PROVEN TO REDUCE:

- 
- HEART FAILURE HOSPITALIZATIONS **BY 58%**³
 - HEART FAILURE 30-DAY READMISSIONS **BY 78%**⁴
 - HFpEF HEART FAILURE HOSPITALIZATIONS **BY 61%**³



99.7%

SAFE AND RELIABLE⁵

99.7% freedom from
device- or system-related
complications³

1. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. *The Lancet*. 2016;387(10017):453-461.
2. Jermyn R, Alam A, Kvasic J, Saeed O, Jorde U. Hemodynamic-guided heart-failure management using a wireless implantable sensor: Infrastructure, methods, and results in a community heart failure disease-management program. *Clinical Cardiology*. 2016. doi:10.1002/clc.22643.
3. Shavelle DM, Desai AS, Abraham WT, et al. Pulmonary artery pressure-guided therapy for ambulatory heart failure patients in clinical practice: 1-year outcomes from the CardioMEMS post approval study. Presented at: ACC; March 17, 2019.
4. Adamson, et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. *Circulation: Heart Failure*. 2016;115.002600.
5. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. *The Lancet*. 2011;377(9766):658-666.

Abbott

One St. Jude Medical Dr., St. Paul, MN 55117 USA
Tel: 1 651 756 2000
cardiovascular.abbott

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications and Usage: The CardioMEMS™ HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure patients who have been hospitalized for heart failure in the previous year. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations.

Contraindications: The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

Potential Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to, the following: Infection, Arrhythmias, Bleeding, Hematoma, Thrombus, Myocardial infarction, Transient ischemic attack, Stroke, Death, and Device embolization.

™ Indicates a trademark of the Abbott group of companies.
© 2020 Abbott. All Rights Reserved.
39146 MAT-2003851 v1.0 | Item approved for U.S. use only.

